ELI LILLY: Possible to start a strong multi week correction.Eli Lilly has seen enormous growth over the past few years and in particularly in 2023. This Channel Up on the log chart's 1W timeframe is the best depiction of the long term trend. The 1W outlook got extremely overbought technically three weeks ago (RSI = 68.989, MACD = 46.590, ADX = 60.019) and is now correcting. The rejection took place at the top of the Channel Up.
This is a hint that investors should be exiting LLY and not entering. Historically the most efficient level to buy is on the 1W MA50 with a max extension to the 1W MA100. That is our entry strategy. Don't take chances and take the best possible entry. This stock will reward us enormously in 2024.
## If you like our free content follow our profile to get more daily ideas. ##
## Comments and likes are greatly appreciated. ##
LLYC trade ideas
LLY, This ALL-TIME-HIGH ROCKET is a NEVER ENDING STORY!Hello There!
Welcome to my new analysis about LLY on several timeframe perspectives. LLY printed an major bullish breakout literally over night bouncing out of the range. In the recent times the pharma industry transformed into a eager bullish environment since the gains seen because of the "pandemic" and LLY is a stock already present since 1978 in the 19th century, a time before the great depression. The FED is considering a more dovish policy as inflationary pressures in the U.S. decreased and LLY showed an development typical for more bullish stocks within the market, it already bounced before the U.S. CPI release signaled an easing in inflation, such moves are always important to anticipate as it is the case with LLY and the long direction.
Within the chart LLY is now forming a flag-formation on the local term which is likely to complete with a breakout in the near future setting up the next wave C extension into the upper directions. On the global term LLY bounced several times within the ascending trendline and has an underlying strong volatility-spike structure which is bolstering the bullish sentiment here. Once LLY has shown up with the breakout dynamics and reached the targets of the local formation this is likely to convert into the continuation of the global trend as well. Currently, the bullish scenario should be considered if the FED does not become more hawkish on interest rates or there is a major demand shortage increasing supply within the pharma market this should be a considerable scenario for the next times.
In this manner, thank you everybody for watching, support is greatly appreciated, all the best!
VP
ELI LILLY Hit the top of the 4-year Channel. Relief sell-off?Earlier this year we gave a strong buy signal on Eli Lilly and Company (LLY) on March 01 (see chart below) where we called for the most optimal buy entry exactly at the bottom of the bullish pattern:
The price has now hit (last week) the top of the 4 year logarithmic Channel Up, highly overbought with the RSI on the 1W time-frame reaching 84.30, breaking above the August 16 2021 High. As last week's 1W candle closed in red (the first after 5 straight bullish weeks) this is considered so far a Higher Highs rejection and calls for an early sell signals towards the end of October, targeting the 1D MA100 (red trend-line) at $500.00, where the stock will start turning into a buy opportunity again (assuming the RSI is below 55.00).
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
$LLY, Price correction?Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Positive:
Yields high return on invested capital
Has raised its dividend for 8 consecutive years
13 analysts have revised their earnings upwards for the upcoming period
Prominent player in the Pharmaceuticals industry
Cash flows can sufficiently cover interest payments
High return over the last year
An analyst from Morgan Stanley maintained Eli Lilly (NYSE: LLY) at 'overweight' with a price target of $640.00 from a prior price target of $617.00.
Negative:
Trading at a high earnings multiple
Corporate insiders Sold shares worth $21.3B in the past 3 months
Hedge funds Sold 789.5K shares in the past quarter
Very strong bullish trend, it is expecting a price correction after this stock should follow
LLY: The NVDA of Pharmaceuticals Showing Signs of Future DeclineIf we close the day as we are now, we will have confirmed a 3 Line Strike, a Bearish PPO Arrow, and a break below the 5 EMA on the Daily Timeframe just above the 3.618 Fibonacci Extension. From there I would expect LLY to first Fill the gap at $451.50 and beyond that I think it will revisit the 200-day SMA around $350 and maybe even the 800-day EMA at around $285.
Eli Lily Local Top, Continuation Will ReturnEli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War
ELI LILLY Approaching the top of the Channel. Sell opportunity.Last time we looked at Eli Lilly and Company (LLY) was on March 01 (see chart below) where we called for the most optimal buy entry exactly at the bottom of the bullish pattern:
The price is now approaching the top of the 3 year logarithmic Channel Up, highly overbought with the RSI on the 1W time-frame at 80.00. This gradually calls for a sell towards the end of August, targeting the 1D MA100 (red trend-line) at $480.00, where the stock will turn into a buy opportunity again.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
LLY Earnings Play LONG ( Flat Bottom Triangle Breakout)My analysis is on the 2H. I am uniquely qualified in my fundamental analysis. This is a one
day until earnings. My thesis is the earnings will stimulate what will be a breakout from
a flat bottom triangle. I will buy one share of stock. I will spend a similar amount on
call options striking $460 expiring August 11th. I see LLY as surging while PFE is a bit
challenged with the fall off in Covid vaccine work. If you find this idea interesting and
might appreciate my ideas as to a stop loss and targets, leave a comment. Like and
subscribe. Trade well !
LLY Eli Lilly Options Ahead of EarningsAnalyzing the options chain and the chart patterns of LLY Eli Lilly prior to the earnings report this week,
I would consider purchasing the 450usd strike price Calls with
an expiration date of 2023-8-11,
for a premium of approximately $11.70.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
LDMR (Long Derivative Mean Reversion)(LDMR)Long Derivative Mean Reversion is primarily a tool for measuring risk and capital efficiency.
It's secondary functions include identify outliers in the assignment value of derivatives, maintaining a price target and producing trade placement recommendations.
This strategy has one simple input: the symbol of a correlated asset or index. It is recommended to use leveraged indexes in this input because they have a higher derivative correlation with those of round lots of the underlying.
When using this strategy you should always adjust the initial capital to what it will cost you to control 100 shares of the security.
If you intend to purchase shares then that value is 100x the close price.
if you intend to purchase call options to resell for premiums you use the initial premiums paid for the calculation.
If you intend to create a synthetic position you should add all deployed capital together, and that calculation will remain accurate until the max profit limit of your short option is reached.
Pyramiding is supported for trade placement. You should always review the historical depth and before placing the first trade ensure you have enough capital to cover the largest of those positions. Otherwise your results may be entirely incomparable to the risk and capital efficiency estimates the tool provides.
Let me know what you think. I am considering a private publishing and want to know what this is worth!
$LLY - SHORT SWING1. Playing the bearish divergence here.
2. Not seen here, but a rise in selling pressure (volume) was seen at the end of the trading day on Friday (4/28).
3. RVOL is slightly up, which is this case shows the bearish volume is higher than typical AKA above average.
4. Oscillator divergence starting to break down as price simultaneously makes newer highs.
Eli Lilly Finally Pulls BackDrug developer Eli Lilly shot to new highs earlier in the year, and now it’s finally pulled back.
The first pattern on today’s chart is the high-volume bullish candle on May 3. The move followed positive Phase 3 data for donanemab, its potential Alzheimer's disease treatment.
Second, prices are trying to hold the rising 21-day exponential moving average. That may indicate its short-term uptrend remains in effect.
Third, LLY apparently got ahead of itself last week and was unable to hold a new all-time high. But its quick pullback dragged stochastics to an oversold level where some buyers may feel more comfortable with the risk/reward.
TradeStation has, for decades, advanced the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more.
Important Information
TradeStation Securities, Inc., TradeStation Crypto, Inc., and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., all operating, and providing products and services, under the TradeStation brand and trademark. TradeStation Crypto, Inc. offers to self-directed investors and traders cryptocurrency brokerage services. It is neither licensed with the SEC or the CFTC nor is it a Member of NFA. When applying for, or purchasing, accounts, subscriptions, products, and services, it is important that you know which company you will be dealing with. Please click here for further important information explaining what this means.
This content is for informational and educational purposes only. This is not a recommendation regarding any investment or investment strategy. Any opinions expressed herein are those of the author and do not represent the views or opinions of TradeStation or any of its affiliates.
Investing involves risks. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options, futures, or digital assets); therefore, you should not invest or risk money that you cannot afford to lose. Before trading any asset class, first read the relevant risk disclosure statements on the Important Documents page, found here: www.tradestation.com .
LLY - Sell the Good News??As compelling as the recent drug breakthrough may have been, it seems to have opened up an opportunity - time to short LLY stock?
Healthcare has shown a lot of strength in general this year, but has lately shown it can move independently of the market. For instance, during the August rally, it declined significantly. However, in this September slowdown, it has instead consolidated at nearly the same price level. You could view a short on this stock as a hedge to whatever you may be doing with the index.
LLY in general has been overvalued for a while, especially comparing to other healthcare stocks and even when accounting for future growth. However, a number of strong supports have formed as the stock has gone higher.
I think that a cautious short position would be good here, but pay close attention to the $320 and $300 level. It looks like it has rejected anything higher than the current levels (see bearish top wick & previous triple top.) There could be some news risk.